The Patented Medicine Prices Review Board (PMPRB) has released its 7th edition CompassRX report, Annual Public Drug Plan Expenditure Report for 2019/20. The report was prepared as part of the National Prescription Drug Utilization Information System (NPDUIS), and examines public drug plan expenditures in Canada, including analyzing the main factors that drive annual changes in prescription drug expenditures.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Update on biosimilars in Canada – June 2022
We provide a further update on developments regarding biosimilars in Canada (approvals, pending submissions, litigation, regulatory, market access and competition) since our last update in October 202...Read More -
New PMPRB regulations registered, in force July 1, 2022, interim approach to pricing announced
The amended Patented Medicines Regulations will be coming into force on July 1, 2022 in substantially revised form.Read More -
Final report from advisory panel on potential pan-Canadian formulary is released
As previously reported, on January 11, the Canadian Agency for Drugs and Technologies in Health (CADTH) posted a discussion paper regarding the proposed framework for a potential pan-Cana...Read More